Vemurafenib has been used since 2011 as an inhibitor of v-raf murine sarcoma viral oncogene homolog B1 (BRAF) kinase activity; however, diverse mechanisms of resistance have been identified in melanoma, which often leads to disease progression in patients carrying this mutation [19]. The gene discussed is BRAF; the disease is melanoma.